The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up.

G. Saglio

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis

Honoraria - Bristol-Myers Squibb; Novartis

H. Kantarjian

Consultant or Advisory Role - Novartis

Research Funding - Bristol-Myers Squibb; Novartis; Pfizer

J. Reiffers

Honoraria - Bristol-Myers Squibb

S. Jootar

No relevant relationships to disclose

M. E. Kalaycio

Honoraria - Novartis

Research Funding - Bristol-Myers Squibb; Novartis

H. Shibayama

Research Funding - Novartis

X. Fan

Employment or Leadership Position - Novartis

N. J. Gallagher

Employment or Leadership Position - Novartis

Stock Ownership - Novartis

Y. Shou

Employment or Leadership Position - Novartis

Stock Ownership - Novartis

R. A. Larson

Consultant or Advisory Role - Novartis

Honoraria - Novartis

Research Funding - Novartis

T. P. Hughes

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis

A. Hochhaus

Research Funding - Bristol-Myers Squibb; Novartis